(Q38181699)

30 August 2017

Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia (English)

1 reference

30 August 2017

0 references

0 references

2

James D Chalmers

1 reference

30 August 2017

1

Aran Singanayagam

1 reference

30 August 2017

27 June 2013

1 reference

The Lancet. Respiratory medicine

30 August 2017

1 reference

30 August 2017

1

1 reference

30 August 2017

8

1 reference

30 August 2017

653-662

1 reference

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Early management of younger adults dying of community acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Community acquired pneumonia: aetiology and usefulness of severity criteria on admission

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Guidelines for the management of adult lower respiratory tract infections--full version

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

[Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)]

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Japanese guidelines for the management of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Causes and Factors Associated With Early Failure in Hospitalized Patients With Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Respiratory antibiotic use and clostridium difficile infection: is it the drugs or is it the doctors?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Does early review by a respiratory physician lead to a shorter length of stay for patients with non-severe community-acquired pneumonia?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Microbiological Testing and Outcome of Patients With Severe Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

The Role of Atypical Pathogens in Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A(H1N1) infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Pneumonia caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Legionellosis: Why should I test and report?

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

A prediction model for community-acquired Chlamydia pneumoniae pneumonia in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Antibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit: Impact of Adherence to Infectious Diseases Society of America Guidelines on Survival

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming From the Community With Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Health care-associated pneumonia and community-acquired pneumonia: a single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Guidelines for the management of adult lower respiratory tract infections - Summary

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Microbial aetiology of community-acquired pneumonia and its relation to severity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Optimal therapy for severe pneumococcal community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Prospective study of the aetiology and outcome of pneumonia in the community

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Update in community-acquired and nosocomial pneumonia 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Severity assessment in community-acquired pneumonia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

British Thoracic Society adult community acquired pneumonia audit 2009/10

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Hypoxemia adds to the CURB-65 pneumonia severity score in hospitalized patients with mild pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia--a propensity-adjusted analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Community-acquired pneumonia in outpatients: aetiology and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Hospitalization for Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

Identifying barriers to the rapid administration of appropriate antibiotics in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970084-5

7 January 2021

10.1016/S2213-2600(13)70084-5

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24461668